Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Reliv International, based in Chesterfield, MO, produces nutritional supplements t...
Reliv International, based in Chesterfield, MO,...
Unum Therapeutics is a clinical-stage biopharmaceutical company focused on develop...
Unum Therapeutics is a clinical-stage biopharma...
Restoration Robotics, Inc., (San Jose, CA) is a medical device company developing ...
Restoration Robotics, Inc., (San Jose, CA) is a...
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based, vertically integrate...
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a Sa...
Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets ultrasoni...
Misonix, Inc. (Nasdaq: MSON) designs, develops,...
Check-Cap is a clinical-stage medical diagnostics company developing C-ScanÂŽ, the...
Check-Cap is a clinical-stage medical diagnosti...
Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the de...
Kala Pharmaceuticals, Inc. (Kala) is a biopharm...
Join the National Investor Network and get the latest information with your interests in mind.